China Pharma Holdings, Inc.

For the year ended December 31, 2019, revenue decreased 11.4% to $11.0 million from $12.3 million in 2018. Gross profit was $1.5 million versus $2.0 million last year, and gross margin was 13.6% compared with 16.0%. Net loss was $20.7 million, or $0.48 per basic and diluted share, versus a net loss of $10.8 million, or $0.25 per share, in 2018. The company recorded $17.02 million of impairment loss in 2019, compared with $6.48 million in 2018. Cash and cash equivalents were $1.1 million at December 31, 2019, down from $1.2 million a year earlier, and working capital deficit increased to $4.5 million from $1.3 million. Cash flow from operating activities was $0.6 million in 2019 versus $1.9 million in 2018. Management did not provide formal next-quarter or full-year guidance, but said it will continue focusing on business development and sales and that remaining formulas may be resumed if sufficient funding and other favorable conditions arise.

Management framed 2019 as a difficult year shaped by Chinese pharmaceutical policy changes, including healthcare insurance cost controls, GPO procurement requirements, consistency evaluation, and lower drug expenditure ratios. Zhilin Li said these pressures led the company to impair all advances for its remaining four pipeline products in 2019, though the company may resume development later if funding and conditions improve. The tone was cautious but still opportunistic, with emphasis on expanding into comprehensive healthcare and leveraging existing capabilities.

On the financial side, Sam Hsing reported revenue of $11.0 million, gross profit of $1.5 million, gross margin of 13.6%, and a net loss of $20.7 million, reflecting the impact of the $17.02 million impairment charge. Selling expenses declined to $2.4 million from $3.2 million, while general and administrative expenses increased to $2.3 million from $1.9 million. Cash and cash equivalents were $1.1 million, working capital deficit widened to $4.5 million, and operating cash flow was $0.6 million, underscoring a constrained liquidity position.

There was no substantive analyst Q&A in the transcript, so no specific investor concerns or management rebuttals were covered. The closest thing to a Q&A was management’s closing invitation for questions, but the call ended without any being asked. As a result, the main open issues remain the company’s liquidity, the impairment of pipeline assets, and how policy pressure affects future sales.